Genomatix said this week that its software has been selected to analyze next-generation sequence data for the Blueprint of Hematopoietic Epigenomes consortium, an EU-funded project focused on research into blood-based diseases like leukemia.
Genomatix also said that it will develop a graphical user interface for the consortium that will help researchers view the project's results.
Genomatix is one of 41 partners in the €40 million ($54 million) Blueprint project, which aims to generate 100 reference epigenomes and study their underlying biological processes and mechanisms in relation to health and disease.
The project kicked off in late September and is slated to run through March 2016. It has received €30 million in funding from the European Commission and will receive an additional contribution of nearly €10 million from collaborators.
Specifically, the consortium will study different types of hematopoietic cells in samples taken from healthy individuals and leukemia patients. The researchers are hoping to identify epigenetic targets for drugs as well as to discover and validate markers for diagnostic use.
Korbinian Grote, Genomatix's product manager, said in a statement that the project will help the company "further improve our existing line of next-generation sequencing analysis products" as well as implement "new ideas tailored towards the integration of epigenomic data into our interfaces and visualizations."